Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Income from Continuing Operations (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Income from Continuing Operations for 4 consecutive years, with 28629000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 61.78% to 28629000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 183204000.0 through Dec 2025, up 36.21% year-over-year, with the annual reading at 183204000.0 for FY2025, 36.21% up from the prior year.
  • Income from Continuing Operations hit 28629000.0 in Q4 2025 for Axsome Therapeutics, up from 47229000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11238000.0 in Q1 2023 to a low of 98651000.0 in Q4 2023.
  • Historically, Income from Continuing Operations has averaged 56050437.5 across 4 years, with a median of 60327000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 71.64% in 2023 and later tumbled 508.27% in 2024.
  • Year by year, Income from Continuing Operations stood at 61241000.0 in 2022, then crashed by 61.09% to 98651000.0 in 2023, then increased by 24.06% to 74912000.0 in 2024, then surged by 61.78% to 28629000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for AXSM at 28629000.0 in Q4 2025, 47229000.0 in Q3 2025, and 47933000.0 in Q2 2025.